ImmuCell Corporation (ICCC)

Currency in USD
11.170
-0.080(-0.71%)
Closed·
11.1700.000(0.00%)
·
ICCC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.10011.495
52 wk Range
4.52012.100
Key Statistics
Prev. Close
11.17
Open
11.273
Day's Range
11.1-11.495
52 wk Range
4.52-12.1
Volume
12.69K
Average Volume (3m)
14.43K
1-Year Change
142.8261%
Book Value / Share
3.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICCC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

ImmuCell Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

ImmuCell Corporation Earnings Call Summary for Q3/2026

  • Q3 revenue surged 46% to $8.0M; net income hit $1.0M vs. $140K loss year-ago; gross margin improved to 44.2% from 42.9%
  • Nine-month revenue rose 27.8% to $25.6M; adjusted EBITDA climbed 66% to $7.3M; working capital increased to $16.9M from $13.0M
  • Company refocused strategy on First Defense bovine products after resolving supply bottlenecks; international sales jumped 573% to $1.1M
  • Investing $8.0M in capacity expansion; new freeze dryer expected H1 2027 to triple drying capacity; liquids expansion due by end-2027
  • Management discontinued Re-Tain mastitis project; focusing on lowering costs, international expansion, and maximizing First Defense returns
Last Updated: 14/11/2026, 01:40 am
Read Full Transcript

Earnings

Latest Release
12/11/2026
EPS / Forecast
0.10 / --
Revenue / Forecast
8.04M / --
EPS Revisions
Last 90 days

ICCC Income Statement

Compare ICCC to Peers and Sector

Metrics to compare
ICCC
Peers
Sector
Relationship
P/E Ratio
54.0x6.8x−0.2x
PEG Ratio
−2.26−0.280.00
Price/Book
3.1x2.4x2.6x
Price / LTM Sales
3.1x4.8x2.7x
Upside (Analyst Target)
-255.4%72.2%
Fair Value Upside
Unlock28.4%12.4%Unlock

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Employees
73

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
465.80K5.13%5.24M
Other Institutional Investors
2.61M28.78%29.40M
Public Companies & Retail Investors
6.00M66.10%67.53M
Total
9.08M100.00%102.17M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SRK Fund I, LP5.53%502,2585,650
SRK Capital, LLC5.53%502,2585,650

People Also Watch

36.48
PCRX
+0.05%
63.49
PDEX
-0.70%
152.01
LAMR
-3.63%
93.04
HALO
-2.88%
74.12
ASH
-2.98%

FAQ

What Is the ImmuCell (ICCC) Stock Price Today?

The ImmuCell stock price today is 11.170 USD.

What Stock Exchange Does ImmuCell Trade On?

ImmuCell is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ImmuCell?

The stock symbol for ImmuCell is "ICCC."

What Is the ImmuCell Market Cap?

As of today, ImmuCell market cap is 101.450M USD.

What Is ImmuCell's Earnings Per Share (TTM)?

The ImmuCell EPS (TTM) is 0.21.

From a Technical Analysis Perspective, Is ICCC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has ImmuCell Stock Split?

ImmuCell has split 1 times.

How Many Employees Does ImmuCell Have?

ImmuCell has 73 employees.

What is the current trading status of ImmuCell (ICCC)?

As of 20/11/2026, ImmuCell (ICCC) is trading at a price of 11.170 USD, with a previous close of 11.170 USD. The stock has fluctuated within a day range of 11.100 USD to 11.495 USD, while its 52-week range spans from 4.520 USD to 12.100 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.